• Curr Med Res Opin · Mar 2021

    Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.

    • Siddhi Korgaonkar, Yi Yang, Benjamin Banahan, and John P Bentley.
    • Department of Pharmacy Administration, The University of Mississippi, University, MS, USA.
    • Curr Med Res Opin. 2021 Mar 1; 37 (3): 343-356.

    ObjectiveTo evaluate comparative effectiveness and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) versus warfarin in Medicare beneficiaries with non-valvular atrial fibrillation (NVAF) and comorbid diabetes mellitus (DM).MethodsA retrospective cohort study using 2014-2016 5% national Medicare data was undertaken. NVAF patients with DM aged ≥65 years having at least one prescription for NOACs or warfarin between July 2014 and December 2015 were included in the study. Propensity score matching was used to balance demographic and baseline clinical characteristics of patients in two treatment groups. Cardiovascular outcomes including stroke/systemic embolism (SE) and myocardial infarction (MI) were evaluated to measure effectiveness. Assessment of safety outcomes included intracranial hemorrhage (ICH), major gastrointestinal bleeding (MGB), bleeding from other sites (OB) and all-cause mortality. Stratified Cox proportional hazards models were used to estimate hazard ratios for the outcomes in the matched cohort.ResultsThe matched sample consisted of 4582 patients (2291 pairs). Compared to warfarin, NOACs had a significantly lower risk of stroke/SE (hazard ratio (HR): 0.373, 95% confidence interval (CI): 0.247-0.564, p < .001) and all-cause mortality (HR: 0.783, CI: 0.656-0.873, p = .007). NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300-0.834, p = .008) and OB (HR: 0.608, CI: 0.424-0.870, p = .007), but no difference was observed in the risk of MGB (HR: 0.862, CI: 0.640-1.160, p = .326) between NOACs and warfarin. The composite outcome demonstrated superior overall effectiveness and safety of NOAC therapy compared to warfarin therapy (HR: 0.685, CI: 0.587-0.801, p < .001).ConclusionOral anticoagulation therapy with NOACs was found to be more effective than warfarin therapy among older adults with NVAF and comorbid DM.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…